86 related articles for article (PubMed ID: 6308149)
1. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Laihinen A; Lönnberg P
J Neural Transm Suppl; 1983; 18():279-86. PubMed ID: 6308149
[TBL] [Abstract][Full Text] [Related]
2. Brain neurotransmitters and neuropeptides in Parkinson's disease.
Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
[TBL] [Abstract][Full Text] [Related]
3. Brain enkephalin receptors in Parkinson's disease.
Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
[TBL] [Abstract][Full Text] [Related]
4. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
Ahlskog JE; Richelson E; Nelson A; Kelly PJ; Okazaki H; Tyce GM; van Heerden JA; Stoddard SL; Carmichael SW
Ann Neurol; 1991 Aug; 30(2):185-91. PubMed ID: 1654766
[TBL] [Abstract][Full Text] [Related]
5. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
6. Peculiarities of L: -DOPA treatment of Parkinson's disease.
Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease as a model for changes in dopamine receptor dynamics with aging.
Rinne UK
Gerontology; 1982; 28 Suppl 1():35-52. PubMed ID: 7044903
[TBL] [Abstract][Full Text] [Related]
8. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
9. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
[TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors in the Parkinsonian brain.
Rinne UK; Lönnberg P; Koskinen V
J Neural Transm; 1981; 51(1-2):97-106. PubMed ID: 6114985
[TBL] [Abstract][Full Text] [Related]
11. Studies on aging processes.
Agnati LF; Fuxe K; Benfenati F; Toffano G; Cimino M; Battistini N; Calza L; Merlo Pich E
Acta Physiol Scand Suppl; 1984; 532():45-61. PubMed ID: 6093434
[TBL] [Abstract][Full Text] [Related]
12. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Rinne UK; Marttila R
Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
[TBL] [Abstract][Full Text] [Related]
13. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Chen L; Togasaki DM; Langston JW; Di Monte DA; Quik M
Neuroscience; 2005; 132(2):409-20. PubMed ID: 15802193
[TBL] [Abstract][Full Text] [Related]
14. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.
Piccini P; Weeks RA; Brooks DJ
Ann Neurol; 1997 Nov; 42(5):720-6. PubMed ID: 9392571
[TBL] [Abstract][Full Text] [Related]
15. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
16. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
Kish SJ; Tong J; Hornykiewicz O; Rajput A; Chang LJ; Guttman M; Furukawa Y
Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
[TBL] [Abstract][Full Text] [Related]
17. [Patients with Parkinson disease: functional analysis of dopamine receptors by bromocriptine- thyrotropin-releasing hormone test].
Díaz F; Liberman C; Chariá P
Rev Med Chil; 1991 Mar; 119(3):252-7. PubMed ID: 1842116
[TBL] [Abstract][Full Text] [Related]
18. Does treatment with dopamine agonists affect utilization of exogenous levodopa in the parkinsonian striatum?
Melamed E
J Neural Transm Suppl; 1995; 45():57-60. PubMed ID: 8748609
[TBL] [Abstract][Full Text] [Related]
19. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor function in Parkinson's disease--in vivo studies with prolactin responses.
Laihinen A; Rinne UK
Adv Neurol; 1987; 45():249-52. PubMed ID: 3103387
[No Abstract] [Full Text] [Related]
[Next] [New Search]
